Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Liposomal and Lipid-Based Drug Delivery Systems and Vaccines"
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: closed (28 February 2023) | Viewed by 6239
Special Issue Editor
Interests: liposomes; lipid-based formulations; drug delivery; lipid chemistry; synthesis; lipophilic prodrugs; vaccines; immunotherapy
Special Issue Information
After the discovery of liposomes by Bangham in the early 1960s, they have been explored extensively, both as vehicles for drug delivery and as adjuvant carriers in vaccinology, starting from the first works by Gregoriadis, Ryman, and Allison in the 1970s. The advantage of liposomal and related lipid-based formulations lies in their flexibility, high biocompatibility, and multifunctionality. Nowadays, along with significant successes in the production and clinical implementation of traditional small molecule drugs in liposomal formulations for the treatment of oncological diseases, the first lipid-based formulations for gene therapy are being introduced in clinics. Finally, against the background of pandemic challenges, it is noteworthy to cite Gregory Gregoriadis, “that it took fifty or so years for the two technologies, mRNA and lipid vesicles, to come together at more or less the same time of their need” (https://doi.org/10.1016/j.medidd.2021.100104).
This Special Issue is addressed to those authors who are currently engaged in research on the use of liposomes, lipid nanoparticles (non-vesicular supramolecular systems, as opposed to classical liposomes), and other lipid-based formulations for the development of drug delivery systems and vaccines. The issue is aimed at considering a wide variety of the aspects surrounding the creation and characterization of lipid-based formulations (structural and functional), including delivery systems for small molecule drugs, peptides, oligonucleotides, aptamers, proteins, antibodies, and nucleic acid molecules. Systems for the targeted delivery of therapeutic agents, both to organs and tissues and to intracellular organelles, will also be considered in the scope. The undesirable effects mediated by the immune system in response to the introduction of lipid-based formulations (such as hypersensitivity reactions and others) and the mechanisms of their emergence will also be addressed.
Dr. Elena L. Vodovozova
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- lipid nanoparticles
- lipid-based formulations
- drug delivery
- gene delivery
- mRNA and saRNA